AntalGenics cierra en Capital Cell una ronda de 807.723 € para lanzar un neurofármaco que elimina el picor crónico de la Psoriasis

by Capital Cell

La valoración pre-money de AntalGenics es de 6M euros. Entre los inversores que han participado en el cierre de la ronda destacan varios leads investors como Inveready, Antonio Ferrer y Antonio Paren...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Ares Raises $12.7 Billion to Invest in A...

by Ares Management Corporation

Investors representing approximately $4.0 billion of commitments in Pa...

Photos Stream